Purchase our gastrointestinal diseases module on a standalone basis or together with other modules and solutions across our full portfolio to create an integrated, tailor-made research platform.
Gastrointestinal (GI) diseases have long been a target for the pharmaceutical industry. Previous blockbusters, such as Prilosec, focused on the treatment of gastroesophageal reflux disease (GERD) and ulcers.
The current pharmaceutical focus within GI involves various autoimmune disorders such as Crohn’s disease and ulcerative colitis. As a result, much of the current research focus in this area involves immunosuppressive therapies.
GlobalData's therapy module includes coverage from prevalent diseases such as GERD to niche indications such as celiac disease.